Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma

• Published in: PloS one 2016-03, Vol.11 (3), p.e0149873-e0149873
• Main Authors: Hurabielle, Charlotte, Pillebout, Evangéline, Stehlé, Thomas, Pagès, Cécile, Roux, Jennifer, Schneider, Pierre, Chevret, Sylvie, Chaffaut, Cendrine, Boutten, Anne, Mourah, Samia, Basset-Seguin, Nicole, Vidal-Petiot, Emmanuelle, Lebbé, Céleste, Flamant, Martin
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Biology and Life Sciences; Biopsy; Care and treatment; Creatinine; Creatinine - blood; Cystatin C; Cystatin C - blood; Dermatology; Dosage and administration; Female; Glomerular Filtration Rate; Humans; Impairment; Indoles - adverse effects; Indoles - therapeutic use; Inhibition; Kidney - drug effects; Kidney - physiopathology; Kidney diseases; Kidney Function Tests; Male; Medical personnel; Medicine and Health Sciences; Melanoma; Melanoma - blood; Melanoma - drug therapy; Melanoma - physiopathology; Middle Aged; Nonsteroidal anti-inflammatory drugs; Patients; Physicians; Physiology; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Renal function; Renal Insufficiency - blood; Renal Insufficiency - chemically induced; Renal Insufficiency - physiopathology; Retrospective Studies; Secretion; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Urine; Vemurafenib
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0149873

Serum creatinine has been reported to increase in patients receiving Vemurafenib, yet neither the prevalence nor the mechanism of this adverse event are known. We aimed to evaluate the frequency and the mechanisms of increases in plasma creatinine level in patients receiving Vemurafenib for advanced melanoma. We performed a retrospective monocentric study including consecutive patients treated with Vemurafenib for an advanced melanoma. We collected clinical and biological data concerning renal function before introduction of Vemurafenib and in the course of monthly follow-up visits from March 2013 to December 2014. Cystatin C-derived glomerular filtration rate was evaluated before and after Vemurafenib initiation, as increase in serum cystatin C is specific to a decrease in the glomerular filtration rate. We also performed thorough renal explorations in 3 patients, with measurement of tubular secretion of creatinine before and after Vemurafenib initiation and a renal biopsy in 2 patients. 70 patients were included: 97% of them displayed an immediate, and thereafter stable, increase in creatinine (+22.8%) after Vemurafenib initiation. In 44/52 patients in whom Vemurafenib was discontinued, creatinine levels returned to baseline. Serum cystatin C increased, although proportionally less than serum creatinine, showing that creatinine increase under vemurafenib was indeed partly due to a renal function impairment. In addition, renal explorations demonstrated that Vemurafenib induced an inhibition of creatinine tubular secretion. Thus, Vemurafenib induces a dual mechanism of increase in plasma creatinine with both an inhibition of creatinine tubular secretion and slight renal function impairment. However, this side effect is mostly reversible when Vemurafenib is discontinued, and should not lead physicians to discontinue the treatment if it is effective.